376 related articles for article (PubMed ID: 35277538)
1. Computational identification of host genomic biomarkers highlighting their functions, pathways and regulators that influence SARS-CoV-2 infections and drug repurposing.
Mosharaf MP; Reza MS; Kibria MK; Ahmed FF; Kabir MH; Hasan S; Mollah MNH
Sci Rep; 2022 Mar; 12(1):4279. PubMed ID: 35277538
[TBL] [Abstract][Full Text] [Related]
2. Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches.
Ahmed FF; Reza MS; Sarker MS; Islam MS; Mosharaf MP; Hasan S; Mollah MNH
PLoS One; 2022; 17(4):e0266124. PubMed ID: 35390032
[TBL] [Abstract][Full Text] [Related]
3. Bioinformatics-based investigation on the genetic influence between SARS-CoV-2 infections and idiopathic pulmonary fibrosis (IPF) diseases, and drug repurposing.
Islam MA; Kibria MK; Hossen MB; Reza MS; Tasmia SA; Tuly KF; Mosharof MP; Kabir SR; Kabir MH; Mollah MNH
Sci Rep; 2023 Mar; 13(1):4685. PubMed ID: 36949176
[TBL] [Abstract][Full Text] [Related]
4. Identification of host genomic biomarkers from multiple transcriptomics datasets for diagnosis and therapies of SARS-CoV-2 infections.
Sarker B; Rahaman MM; Islam MA; Alamin MH; Husain MM; Ferdousi F; Ahsan MA; Mollah MNH
PLoS One; 2023; 18(3):e0281981. PubMed ID: 36913345
[TBL] [Abstract][Full Text] [Related]
5. Bioinformatics Screening of Potential Biomarkers from mRNA Expression Profiles to Discover Drug Targets and Agents for Cervical Cancer.
Reza MS; Harun-Or-Roshid M; Islam MA; Hossen MA; Hossain MT; Feng S; Xi W; Mollah MNH; Wei Y
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409328
[TBL] [Abstract][Full Text] [Related]
6. Meta-Data Analysis to Explore the Hub of the Hub-Genes That Influence SARS-CoV-2 Infections Highlighting Their Pathogenetic Processes and Drugs Repurposing.
Mosharaf MP; Kibria MK; Hossen MB; Islam MA; Reza MS; Mahumud RA; Alam K; Gow J; Mollah MNH
Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016137
[TBL] [Abstract][Full Text] [Related]
7. Integrative transcriptomics analysis of lung epithelial cells and identification of repurposable drug candidates for COVID-19.
Islam T; Rahman MR; Aydin B; Beklen H; Arga KY; Shahjaman M
Eur J Pharmacol; 2020 Nov; 887():173594. PubMed ID: 32971089
[TBL] [Abstract][Full Text] [Related]
8. Differential Co-Expression Network Analysis Reveals Key Hub-High Traffic Genes as Potential Therapeutic Targets for COVID-19 Pandemic.
Hasankhani A; Bahrami A; Sheybani N; Aria B; Hemati B; Fatehi F; Ghaem Maghami Farahani H; Javanmard G; Rezaee M; Kastelic JP; Barkema HW
Front Immunol; 2021; 12():789317. PubMed ID: 34975885
[TBL] [Abstract][Full Text] [Related]
9. IFI44 is an immune evasion biomarker for SARS-CoV-2 and
Zheng Q; Wang D; Lin R; Lv Q; Wang W
Front Immunol; 2022; 13():1013322. PubMed ID: 36189314
[TBL] [Abstract][Full Text] [Related]
10. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
11. Identification of common molecular signatures of SARS-CoV-2 infection and its influence on acute kidney injury and chronic kidney disease.
Zhang W; Liu L; Xiao X; Zhou H; Peng Z; Wang W; Huang L; Xie Y; Xu H; Tao L; Nie W; Yuan X; Liu F; Yuan Q
Front Immunol; 2023; 14():961642. PubMed ID: 37026010
[TBL] [Abstract][Full Text] [Related]
12. Repurposing novel therapeutic candidate drugs for coronavirus disease-19 based on protein-protein interaction network analysis.
Adhami M; Sadeghi B; Rezapour A; Haghdoost AA; MotieGhader H
BMC Biotechnol; 2021 Mar; 21(1):22. PubMed ID: 33711981
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous Inhibition of SARS-CoV-2 Entry Pathways by Cyclosporine.
Prasad K; Ahamad S; Kanipakam H; Gupta D; Kumar V
ACS Chem Neurosci; 2021 Mar; 12(5):930-944. PubMed ID: 33606519
[TBL] [Abstract][Full Text] [Related]
14. Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing.
Das AB
BMC Med Genomics; 2021 Sep; 14(1):226. PubMed ID: 34535131
[TBL] [Abstract][Full Text] [Related]
15. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
16. Bioinformatics and systems biology analysis revealed PMID26394986-Compound-10 as potential repurposable drug against covid-19.
Nisar H; Wajid B; Anwar F; Ahmad A; Javaid A; Attique SA; Nisar W; Saeed A; Shahid S; Sadaf S
J Biomol Struct Dyn; 2023 Aug; ():1-14. PubMed ID: 37534820
[TBL] [Abstract][Full Text] [Related]
17. Prediction of potential therapeutic drugs against SARS-CoV-2 by using Connectivity Map based on transcriptome data.
Chen WY; Fang ZX; Lv XD; Zhou QH; Yao M; Deng M
Eur Rev Med Pharmacol Sci; 2021 Apr; 25(7):3122-3131. PubMed ID: 33877681
[TBL] [Abstract][Full Text] [Related]
18. Blood transcriptome analysis revealed the crosstalk between COVID-19 and HIV.
Yan C; Niu Y; Wang X
Front Immunol; 2022; 13():1008653. PubMed ID: 36389792
[TBL] [Abstract][Full Text] [Related]
19. Differential gene expression profiling reveals potential biomarkers and pharmacological compounds against SARS-CoV-2: Insights from machine learning and bioinformatics approaches.
Hoque MN; Sarkar MMH; Khan MA; Hossain MA; Hasan MI; Rahman MH; Habib MA; Akter S; Banu TA; Goswami B; Jahan I; Nafisa T; Molla MMA; Soliman ME; Araf Y; Khan MS; Zheng C; Islam T
Front Immunol; 2022; 13():918692. PubMed ID: 36059456
[TBL] [Abstract][Full Text] [Related]
20. Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2.
Anwaar MU; Adnan F; Abro A; Khan RA; Rehman AU; Osama M; Rainville C; Kumar S; Sterner DE; Javed S; Jamal SB; Baig A; Shabbir MR; Ahsan W; Butt TR; Assir MZ
Comput Biol Med; 2022 Feb; 141():105049. PubMed ID: 34823857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
